Does ADT benefit unfavourable intermediate risk prostate cancer patients treated with brachytherapy boost and external beam radiotherapy? A propensity-score matched analysis. (September 2020)

• Record Type: Journal Article
• Authors: Mendez, Lucas C.; Martell, Kevin; Warner, Andrew; Tseng, Chia-Lin; Chung, Hans; Loblaw, Andrew; Rodrigues, George B.; Morton, Gerard
• Is Part Of: Radiotherapy and oncology. Volume 150(2020)
• Page Start: 195
• Page End: 200
• Publication Date: 2020-09
• Subjects: Intermediate risk -- Brachytherapy -- Androgen deprivation; Oncology -- Periodicals; Radiotherapy -- Periodicals; Tumors -- Periodicals; Medical Oncology -- Periodicals; Neoplasms -- radiotherapy -- Periodicals; Radiotherapy -- Periodicals; Radiothérapie -- Périodiques; Cancérologie -- Périodiques; Tumeurs -- Périodiques; Electronic journals; 616.9940642
• DOI: 10.1016/j.radonc.2020.06.039
• Languages: English
• ISSNs: 0167-8140

Abstract

Highlights: Short-term ADT increased BFFS in UIR patients treated with HDT-BT boost. CRFS and MFS were not impacted by ADT use. UIR patients treated with ADT had similar BFFS to favourable intermediate risk (FIR). Abstract: Purpose: To investigate the role of androgen deprivation therapy (ADT) in unfavorable intermediate risk (UIR) prostate cancer patients treated with high-dose rate (HDR) brachytherapy (BT) boost. Material and methods: Data from 326 consecutive NCCN UIR prostate cancer patients treated in a single institution from 2009 to 2016 with 15 Gy HDR-BT boost plus 37.5 Gy external beam radiotherapy (EBRT) in 15 fractions to prostate and proximal seminal vesicles were retrospectively collected. Baseline information was collected and patients receiving vs. not receiving ADT were matched using a propensity-score model. Primary endpoint was biochemical-failure-free survival (BFFS). Kaplan–Meier estimates and stratified log-rank tests (adjusting for matched design) were used to compare BFFS, castration-resistance (CRFS) and metastasis free survival (MFS) outcomes between both groups. Results: A total of 326 patients were included in the analysis of which 52 ADT patients were matched to 104 non-ADT patients in a 1:2 ratio. Median follow-up was 3.4 years and 5.5 years for ADT and non-ADT respectively. No significant baseline differences were observed. ADT was used for a median total time of 6 months (interquartile range [IQR]: 4–6) and delivered a median time of 2.7 months (IQR: 1.7–4.3) prior to HDR-BT. BFFS was significantly improved in the ADT group (stratified log-rank: p = 0.043) with 3-year and 6-year BFFS of 98% and 90% for the ADT group and 92% and 82% for the non-ADT group, respectively. No significant differences were detected for CRFS or MFS. Conclusion: Short-term ADT increased BFFS in UIR prostate cancer patients treated with HDR-BT boost plus EBRT.